甲氧基乙丁基异腈亲肿瘤显像与乳腺癌多药耐药类蛋白关系的研究

The relationship between ^(99m)Tc-MIBI scintimammography of breast cancer and multidrug-resistant proteins

目的研究甲氧基乙丁基异腈(99mTc-MIBI)亲肿瘤显像与乳腺癌多药耐药类蛋白P-糖蛋白(P-gp)、谷胱甘肽-S-转移酶-π(GST-π)和拓扑异构酶Ⅱ(TopoⅡ)的关系。方法对76例未行治疗的乳腺癌患者进行99mTc-MIBI显像,采集10min及180min两时相的平面像,计算放射性清除率;采用免疫组化方法,对术后病理组织进行多药耐药类蛋白检测。结果P-gp阳性组清除率明显高于阴性组,差异有统计学意义;GST-π和TopoⅡ表达率与清除率无明显关系。结论99mTc-MIBI亲肿瘤显像可作为乳腺癌P-gp非组织学测定方法,预测化疗耐药性。

Objective To evaluate the relationship between the clearance rate of technetium-99m methoxyisobutylisonitrile （^99mTe-MIBI） in scintimammography and muhidrug-resistant proteins expression in breast cancer tissues. Methods Seventy-six patients with breast cancer underwent ^99mTc-MIBI scintimammography before treatment, and static planar images were taken at 10 min and 180 min after scintimammography. The clearance rate of ^99mTc-MIBI was calculated in each patient. Immunohistochemical analysis was performed on pathological specimens of the 76 breast tumors to determine the expression of P-glycoprotein （P-gp） ,glutathione S-transferase Pi （GST-π） and topoisomerase Ⅱ （Topo Ⅱ）. Results The clearance rate was significantly higher in 36 patients with positive P-gp expression when compared with that in 40 patients with negative P-gp expression. There was no significant relationship between GST-π, Topo Ⅱ and the clearance rate of ^99mTc-MIBI. Conclusion The clearance rate of ^99mTc-MIBI in breast imaging may be used to evaluate the P-gp level in breast cancers.